Lipoproteins for therapeutic delivery: Recent advances and future opportunities

Sangram Raut, Jean Louis Dasseux, Nirupama A. Sabnis, Linda Mooberry, Andras Lacko

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed.

Original languageEnglish
Pages (from-to)257-268
Number of pages12
JournalTherapeutic Delivery
Volume9
Issue number4
DOIs
StatePublished - 1 Jan 2018

Fingerprint

Lipoproteins
Neoplasms
Triglycerides
Therapeutics
Cholesterol
Pharmaceutical Preparations

Keywords

  • HDL
  • LDL
  • cancer therapy
  • discoidal nanoparticles
  • drug delivery
  • lipoproteins
  • rHDL

Cite this

Raut, Sangram ; Dasseux, Jean Louis ; Sabnis, Nirupama A. ; Mooberry, Linda ; Lacko, Andras. / Lipoproteins for therapeutic delivery : Recent advances and future opportunities. In: Therapeutic Delivery. 2018 ; Vol. 9, No. 4. pp. 257-268.
@article{d68f82b1748f4464ad61ba4b6da26525,
title = "Lipoproteins for therapeutic delivery: Recent advances and future opportunities",
abstract = "The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed.",
keywords = "HDL, LDL, cancer therapy, discoidal nanoparticles, drug delivery, lipoproteins, rHDL",
author = "Sangram Raut and Dasseux, {Jean Louis} and Sabnis, {Nirupama A.} and Linda Mooberry and Andras Lacko",
year = "2018",
month = "1",
day = "1",
doi = "10.4155/tde-2017-0122",
language = "English",
volume = "9",
pages = "257--268",
journal = "Therapeutic Delivery",
issn = "2041-5990",
publisher = "Future Science",
number = "4",

}

Lipoproteins for therapeutic delivery : Recent advances and future opportunities. / Raut, Sangram; Dasseux, Jean Louis; Sabnis, Nirupama A.; Mooberry, Linda; Lacko, Andras.

In: Therapeutic Delivery, Vol. 9, No. 4, 01.01.2018, p. 257-268.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Lipoproteins for therapeutic delivery

T2 - Recent advances and future opportunities

AU - Raut, Sangram

AU - Dasseux, Jean Louis

AU - Sabnis, Nirupama A.

AU - Mooberry, Linda

AU - Lacko, Andras

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed.

AB - The physiological role(s) of mammalian plasma lipoproteins is to transport hydrophobic molecules (primarily cholesterol and triacylglycerols) to their respective destinations. Lipoproteins have also been studied as drug-delivery agents due to their advantageous payload capacity, long residence time in the circulation and biocompatibility. The purpose of this review is to briefly discuss current findings with the focus on each type of formulation's potential for clinical applications. Regarding utilizing lipoprotein type formulation for cancer therapeutics, their potential for tumor-selective delivery is also discussed.

KW - HDL

KW - LDL

KW - cancer therapy

KW - discoidal nanoparticles

KW - drug delivery

KW - lipoproteins

KW - rHDL

UR - http://www.scopus.com/inward/record.url?scp=85043983397&partnerID=8YFLogxK

U2 - 10.4155/tde-2017-0122

DO - 10.4155/tde-2017-0122

M3 - Review article

C2 - 29495929

AN - SCOPUS:85043983397

VL - 9

SP - 257

EP - 268

JO - Therapeutic Delivery

JF - Therapeutic Delivery

SN - 2041-5990

IS - 4

ER -